A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Clinical trial NCT07570017 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07570017
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2026-05-30
- Primary completion
- 2027-12-31
- Enrollment
- 42
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.